These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 38524878)

  • 61. Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.
    Gadde KM; Pritham Raj Y
    Curr Diab Rep; 2017 May; 17(5):34. PubMed ID: 28378293
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
    Halpern B; Mancini MC
    Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study.
    Stefanakis K; Kokkinos A; Argyrakopoulou G; Konstantinidou SK; Simati S; Kouvari M; Kumar A; Kalra B; Kumar M; Bontozoglou N; Kyriakopoulou K; Mantzoros CS
    Diabetes Obes Metab; 2023 Sep; 25(9):2561-2574. PubMed ID: 37246799
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-Term Assessment of Weight Loss Medications in a Veteran Population.
    Rodriguez AD; Ifeachor AP; Moore EA; Otte CF; Schopper MJ; Liangpunsakul S; Lteif AA
    Fed Pract; 2024 Jul; 41(7):202-207. PubMed ID: 39411075
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Review of pharmacotherapy options for the management of obesity.
    Bragg R; Crannage E
    J Am Assoc Nurse Pract; 2016 Feb; 28(2):107-15. PubMed ID: 26119641
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Obesity: Pharmacotherapy.
    Powell A
    FP Essent; 2020 May; 492():25-29. PubMed ID: 32383845
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Drugs for Treating Obesity.
    Ryan DH
    Handb Exp Pharmacol; 2022; 274():387-414. PubMed ID: 34783910
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
    Bays H
    Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines.
    Dong Z; Xu L; Liu H; Lv Y; Zheng Q; Li L
    Obes Rev; 2017 Dec; 18(12):1377-1385. PubMed ID: 29024559
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Review article: Pharmacologic management of obesity - updates on approved medications, indications and risks.
    Lupianez-Merly C; Dilmaghani S; Vosoughi K; Camilleri M
    Aliment Pharmacol Ther; 2024 Feb; 59(4):475-491. PubMed ID: 38169126
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis.
    Khera R; Pandey A; Chandar AK; Murad MH; Prokop LJ; Neeland IJ; Berry JD; Camilleri M; Singh S
    Gastroenterology; 2018 Apr; 154(5):1309-1319.e7. PubMed ID: 29305933
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacotherapy for Obesity.
    Saunders KH; Shukla AP; Igel LI; Kumar RB; Aronne LJ
    Endocrinol Metab Clin North Am; 2016 Sep; 45(3):521-38. PubMed ID: 27519128
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents.
    Lim F; Bellows BK; Tan SX; Aziz Z; Woo Baidal JA; Kelly AS; Hur C
    JAMA Netw Open; 2023 Aug; 6(8):e2329178. PubMed ID: 37651143
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Medications Available for Weight Reduction in Elective Total Joint Arthroplasty.
    Amanatullah DF; Ohanisian L; Bailony R
    JBJS Rev; 2020 Jun; 8(6):e0123. PubMed ID: 33006462
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Meta-analysis: pharmacologic treatment of obesity.
    Li Z; Maglione M; Tu W; Mojica W; Arterburn D; Shugarman LR; Hilton L; Suttorp M; Solomon V; Shekelle PG; Morton SC
    Ann Intern Med; 2005 Apr; 142(7):532-46. PubMed ID: 15809465
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Update on obesity pharmacotherapy.
    Bray GA; Ryan DH
    Ann N Y Acad Sci; 2014 Apr; 1311():1-13. PubMed ID: 24641701
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison table: some FDA-approved drugs for weight management.
    Med Lett Drugs Ther; 2018 Jun; 60(1548):e98-e100. PubMed ID: 29913464
    [No Abstract]   [Full Text] [Related]  

  • 78. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
    Woloshin S; Schwartz LM
    JAMA Intern Med; 2014 Apr; 174(4):615-9. PubMed ID: 24515599
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study.
    Gorgojo-Martínez JJ; Basagoiti-Carreño B; Sanz-Velasco A; Serrano-Moreno C; Almodóvar-Ruiz F
    Int J Clin Pract; 2019 Nov; 73(11):e13399. PubMed ID: 31397946
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Safety and tolerability of medications approved for chronic weight management.
    Fujioka K
    Obesity (Silver Spring); 2015 Apr; 23 Suppl 1():S7-11. PubMed ID: 25900872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.